The UK MDR 2002 Framework: One Regulation for Devices

1. Key takeaways

The United Kingdom does not adopt the European Union model of two parallel regulations — one general regulation for medical devices and one dedicated regulation for in vitro diagnostic medical devices (IVDs). Instead, both categories are governed by a single instrument: The Medical Devices Regulations 2002 (SI 2002/618, as amended, referred to throughout as the UK MDR 2002). The regulation organises devices into three substantive parts: Part II for general devices, Part III for active implantable devices and Part IV for IVDs. Around this core sit supporting parts that cover the remaining compliance lifecycle: Part 4A on post-market surveillance, Part V on conformity assessment bodies, Part VI on fees and Part VII on enforcement. The territorial scope of the UK MDR 2002 is confined to Great Britain; Northern Ireland instead applies Regulation (EU) 2017/745 and Regulation (EU) 2017/746 under the Windsor Framework. For any manufacturer planning a United Kingdom market entry, the first structural fact to internalise is therefore this: one consolidated domestic regulation governs Great Britain, while a separate European legal track governs Northern Ireland, and the two tracks cannot be substituted for one another.

2. Legal basis

The following instruments together define the regulatory framework described in this article, and they must be read as layers rather than as alternatives:

• The Medical Devices Regulations 2002 (SI 2002/618, as amended): Part I, regulations 1–4T (general provisions); Part II, regulations 5–19C; Part III, regulations 20–31; Part IV, regulations 32–44ZB; Part 4A, regulations 44ZC–44ZR; Part V, regulations 44A–51; Part VI, regulations 52–58A; Part VII, regulations 59–67; together with Schedules 1, 2 and 2A.
• The Medical Devices (Amendment) (Great Britain) Regulations 2023 (SI 2023/627, made on 9 June 2023): regulation 4 substitutes regulation 1ZA.
• The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 (SI 2024/1368, made on 16 December 2024, in force from 16 June 2025): regulation 4 inserts Part 4A.
• The Medical Devices (Fees Amendment) Regulations 2026 (SI 2026/197, made on 25 February 2026, in force from 1 April 2026): regulations 3, 4 and 5.
• The Medical Devices (Northern Ireland Protocol) Regulations 2021 (SI 2021/905, made on 26 July 2021, in force from 27 July 2021): regulation 2 (scope).

Reading these instruments in sequence matters. The 2002 parent regulation establishes the architecture; the 2023 amendment adjusts the expiry points of the CE marking transition; the 2024 amendment introduces an entire chapter on post-market surveillance; and the 2026 amendment rewrites the fee provisions. Skipping any layer risks applying rules that no longer exist, or overlooking obligations that entered into force only recently.

3. Expert insights

Insight 1: the three-layer legislative pedigree dictates the reading order. The UK MDR 2002 was originally made under section 2(2) of the European Communities Act 1972, the Consumer Protection Act 1987 and the Finance Act 1973, and it was used to implement three directives: Directive 90/385/EEC, Directive 93/42/EEC and Directive 98/79/EC. After Brexit, the United Kingdom did not build the system from scratch; instead, Schedule 2A applies localised modifications to the annexes of those three directives, so that the annexes continue to serve as the source of the substantive United Kingdom requirements. In practical terms, anyone reading the British rules must consult three documents side by side: the body of the UK MDR 2002, Schedule 2A, and the directive annexes as they are invoked. Omitting any one of the three produces an incomplete picture of the requirements that actually apply, and gaps tend to surface precisely at the moments when documentation is examined by regulators or partners.

Insight 2: the amendment hierarchy determines which provisions are live today. The three recent amendments each have a distinct function: SI 2023/627 adjusts the expiry points of the CE marking transition (regulation 1ZA); SI 2024/1368 adds an entire chapter on post-market surveillance (Part 4A); and SI 2026/197 rewrites the fee provisions (regulation 53). A frequent corporate error is to keep working from outdated flowcharts, treating one-off registration fees and 30-day reporting as if they were still the current rules. Compliance teams should anchor every process map to the amendment that is in force on the date of the activity, and should record the version of the legal basis relied upon in each procedural document so that the position can be reconstructed later.

Insight 3: the Part numbering trap. Part IV covers IVDs, while Part 4A covers post-market surveillance; the two sit numerically adjacent but address entirely unrelated subjects. From 16 June 2025, Part 4A applies to all devices on the Great Britain market, including IVDs and active implantable devices. Confusing the two parts is more than a drafting slip: misreading Part 4A as an IVD-only chapter leads companies to exempt other device categories from surveillance obligations that plainly apply to them, and the resulting gaps are exactly the kind that enforcement and registration checks are designed to expose.

4. Practical recommendations

GRZAN recommends establishing a Great Britain compliance baseline through a three-step positioning method. Step one: confirm whether the product falls under Part II, Part III or Part IV of the UK MDR 2002. Step two: confirm the sales territory — Great Britain, Northern Ireland, or both. Step three: confirm the governing European legal basis (legacy MDD/AIMDD/IVDD certificates, or MDR/IVDR certificates) and work backwards from it to the applicable transition points. Product portfolios with different answers on any of the three steps require three independent ledgers; they cannot be compressed into a single shared United Kingdom compliance checklist. Position first and document second: once the part, the territory and the legal basis are fixed, every downstream obligation — registration, labelling, surveillance and fees — can be mapped deterministically, and future regulatory changes can be traced to the specific ledger entries they affect.

5. Verification checklist

• □ The Part to which the product belongs (Part II / III / IV) has been confirmed
• □ The sales territory (Great Britain / Northern Ireland / both) has been confirmed
• □ The governing European legal basis and certificate status have been confirmed
• □ The current consolidated text of the UK MDR 2002 and Schedule 2A has been obtained
• □ The applicable provisions of SI 2023/627, SI 2024/1368 and SI 2026/197 have been cross-checked

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.